In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ACCA Ivory (& above) Members, Fellows of the ESC and Young combined Members

Neutrophil-to-lymphocyte ratio predicts death in recuperated out-of-hospital cardiac arrest due to coronary artery disease

Session Poster Session 2

Speaker Maria Trepa

Congress : Acute Cardiovascular Care 2019

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Acute Cardiac Care - CCU, Intensive, and Critical Cardiovascular Care
  • Session type : Poster Session
  • FP Number : P559

Authors : M Trepa (Porto,PT), S Bastos (Porto,PT), R Santos (Porto,PT), M Oliveira (Porto,PT), R Costa (Porto,PT), M Santos (Porto,PT), A Luz (Porto,PT), J Silveira (Porto,PT), H Carvalho (Porto,PT), A Albuquerque (Porto,PT), S Torres (Porto,PT)


M Trepa1 , S Bastos2 , R Santos1 , M Oliveira1 , R Costa1 , M Santos1 , A Luz1 , J Silveira1 , H Carvalho1 , A Albuquerque1 , S Torres1 , 1Hospital Center of Porto, Cardiology - Porto - Portugal , 2University of Porto - Porto - Portugal ,


Recuperated out-of-hospital cardiac arrest (rOHCA) population is wide and heterogenous. Few studies focused specifically on outcomes in the rOHCA subgroup with proven significant coronary artery disease (SigCAD). Furthermore, the neutrophil-to-lymphocyte ratio (NLR), a marker of inflammation, is associated with prognosis in acute coronary syndromes but no data exists in patients with SigCAD presenting after rOHCA.
Our aim was to assess the prognostic significance of NLR ratio in this specific subgroup of patients.

Retrospective observational study of rOHCA patients submitted to coronary angiography. SigCAD was defined as >70% stenosis in major vessels or >50% in left main or performance of percutaneous coronary intervention (PCI). The finding of SigCAD was used to establish a coronary cause for OHCA and only those patients were included for further analysis. 
Logistic regression and receiver operator curves (ROC) models were used for statistical analysis.

63 patients were included with a median age of 63 years old  and 84% were male. In-hospital mortality was 36%. In coronary angiography, 90% had at least 1 suboclusive lesion and 73% had a recent total occlusion; 72% underwent PCI.  The median NLR at 24h was 8 (interquartile range: 6.5). Patients with higher NLR were older (57±11yo vs 65±13, p= 0.02), more likely to be non-smokers (74% vs 47%, p=0.04) and to have a higher GRACE score at 24h (151±35 vs 172±31, p= 0.04). No statistically significant difference were found between groups regarding to other clinical characteristics, initial arrest rhythm, EKG changes, initial lactate and troponin values and extent of CAD.

At admission, a pH<7.2 (63% vs 34%, p=0.04) and a non-shockable rhythm (75% vs 34%, p=0.02) were associated with mortality. At 24 hours, only a lactate value >1.7mmol/L (33% vs 66%, p= 0.03) and NLR>8 (13% vs 55% p<0.01) significantly predicted death.

In multivariate analysis including all aforementioned significant predictors, only a 24h NLR>8 remained an independent predictor of in-hospital mortality (p=0.01) increasing the of death risk by 12 fold.

In ROC analysis, a 24h NLR>8 demonstrated a moderate discriminative performance (area under the curve: 0.7) to identify those patients who eventually died.

A 24h NLR>8 in rOHCA patients with SigCAD is significantly associated with in-hospital mortality, even after adjustment for other classical prognostic markers. Our findings suggest inflammation as a critical pathophysiological mechanism and NLR as a potentially novel prognostic marker for these patients.

Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, and Novartis Pharma AG. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are